Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20231723 | 1.00 | ABCB1 (0.48) | ABCB1LMNAMAPTALDH1A1SUV39H2 | |
| SCHEMBL21982731 | 0.87 | NAMPT (0.46) | ABCB1LMNAMAPTALDH1A1SUV39H2 | |
| SCHEMBL22498015 | 0.85 | KDM4E (0.43) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30431090 | 0.82 | LMNA (0.44) | ABCB1LMNAMAPTALDH1A1SUV39H2 | |
| SCHEMBL28534844 | 0.82 | LMNA (0.44) | ABCB1LMNAMAPTALDH1A1SUV39H2 | |
| SCHEMBL20046699 | 0.80 | PDK2 (0.55) | ABCB1LMNAMAPTALDH1A1NAMPT | |
| SCHEMBL29547575 | 0.80 | PDK2 (0.55) | ABCB1LMNAMAPTALDH1A1NAMPT | |
| SCHEMBL31216276 | 0.77 | ABCB1 (0.50) | ABCB1LMNAMAPTALDH1A1SUV39H2 | |
| SCHEMBL20231647 | 0.77 | PDK2 (0.53) | LMNAMAPTALDH1A1SUV39H2NAMPT | |
| SCHEMBL31216180 | 0.76 | ABCB1 (0.50) | ABCB1LMNAMAPTALDH1A1SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118480030-A | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-112262134-B | Cerebulin ligands and bifunctional compounds comprising same | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ASTRAZENECA UK LIMITED (GB) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169643-A1 | ESTROGEN RECEPTOR DEGRADING PROTACS | ESR1, GPER1, ESRRG | ABCB1 776/4885LMNA 1724/4885MAPT 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.